glp-1 agonist and dpp-4 inhibitor How do SGLT-2 inhibitors, agonists, inhibitors compare in reducing #mortality and #cardiovascular events in patients with type 2 #diabetes? Find out GLP-1/GLP-1R: The Star Target for
Description
The compound was originally developed by Eli Lilly and licensed to Innovent Biologics for development and commercialization in China
Additionally, 49% of patients on the 30 mg dose achieved HbA1c levels below 7%, compared to only 21% in the placebo group
Agarwal S, Sasane S, Kumar J, Deshmukh P, Bhayani H, Giri P, et al
Given the principal anti-inflammatory effect of GLP-1 in the central nervous system elucidated in previous sections, research on the role of GLP-1 in the neuro-ophthalmic circuit shows a similar beneficial promise
A reduction in the expression levels of the AGE receptor facilitated this effect
